Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Relative bioavailability of cyclosporin from conventional and microemulsion formulations in heart-lung transplant candidates with cystic fibrosis

  • 24 Accesses

  • 8 Citations

Abstract

Patients with cystic fibrosis absorb cyclosporin poorly and erratically. We have compared the relative bioavailability of cyclosporin from conventional and microemulsion formulations in 5 adult heart-lung transplant candidates with cystic fibrosis. Relative bioavailability was compared at two dose levels (200 mg and 800 mg). A randomized 4-period cross-over study was performed with at least a 7 days washout period between each single dose pharmacokinetic study. Blood cyclosporin concentrations were measured by a selective monoclonal antibody-based radioimmunoassay. The bioavailability of cyclosporin from the microemulsion formulation was 1.84 (95% C.I. 1.05 to 3.22; P−0.04) and 2.09 (95% C.I. 0.95 to 4.61; P−0.06) times higher compared with the conventional formulation at 200 mg and 800 mg respectively. Cmax following the microemulsion formulation was 3.38 (C.I. 1.14 to 10.59; P−0.04) and 2.77 (C.I. 1.48 to 5.19; P−0.01) times higher compared with the conventional formulation at 200 mg and 800 mg respectively. The higher Cmax following the microemulsion formulation was accompanied by shorter tmax. An enhancement of cyclosporin absorption with the microemulsion formulation was demonstrated in each patient for at least one dose level. We conclude that rate and extent of cyclosporin absorption from the microemulsion formulation is greater compared with the conventional formulation in patients with cystic fibrosis. The potential therapeutic and economic benefits of the micro-emulsion formulation should be evaluated in cystic fibrosis patients following heart-lung transplantation.

This is a preview of subscription content, log in to check access.

References

  1. Cooney GF, Fiel SB, Shaw LM, Cavarocchi NC (1990) Cyclosporine bioavailability in heart-lung transplant candidates with cystic fibrosis. Transplantation 49:821–823

  2. Gardner MJ, Altman DG (1989) Statistics with confidence

  3. Mancel-Grosso V, Bertault-Peres P, Barthelemy A, Chazalette JP, Durand A, Noirclerc M (1990) Pharmacokinetics of cyclosporin A in bilung transplantation candidates with cystic fibrosis. Transplant Proc 22:1706–1707

  4. Mehta MU, Venkataramanan R, Burckart GJ, Ptachinski RJ, Delamos B, Stachak S, Van Thiel DH, Iwatsuki S, Starzl TE (1988) Effect of bile on cyclosporin absorption in liver transplant patients. Br J Clin Pharmacol 25:579–584

  5. Mueller EA, Kovarik JM, Bree JB van, Tetzloff W, Grevel J, Kutz K (1994a) Improved dose linearity of cyclosporine pharmacokinetics from a microemulsion formulation. Pharm Res 11:301–304

  6. Mueller EA, Kovarik JM, Bree JB van, Lison AE, Kutz K (1994b) Pharmacokinetics and tolerability of a microemulsion formulation of cyclosporine in renal allograft recipients-a concentration-controlled comparison with the commercial formulation. Transplantation 57:1178–1182

  7. Nagel RA, Westaby D, Javaid A, Kavani J, Meire HB, Lombard MG, Wise A, Williams R, Hodson ME (1989) Liver disease and bile duct abnormalities in adults with cystic fibrosis. Lancet 2:1422–1425

  8. Reymond J-P, Steimer J-L, Niederberger W (1988) On the dose dependency of cyclosporin A absorption and disposition in healthy volunteers. J Pharmacokinet Biopharm 16:331–353

  9. Tan KKC, Hue KL, Strickland S, Trull AK, Smyth RL, Scott JP, Kelman AW, Whiting B, Higenbottam TW, Wallwork J (1990) Altered pharmacokinetics of cyclosporin in heart-lung transplant recipients with cystic fibrosis. Ther Drug Monit 12:520–524

  10. Tan KKC, Trull AK, Hue KL, Best NG, Wallwork J, Higenbottam TW (1993) Pharmacokinetics of cyclosporine in heart and lung transplant candidates and recipients with cystic fibrosis and Eisenmenger's syndrome. Clin Pharmacol Ther 53:544–554

  11. Trull AK, Tan KKC, Uttridge J, Bauer T, Alexander GJM, Jamieson NV (1993) Cyclosporin absorption from a microemulsion formulation in liver transplant recipient. Lancet 341:433

  12. Trull AK, Tan KKC, Tan L, Alexander GJM, Jamieson NV (1994) Enhanced absorption of a new oral cyclosporin microemulsion formulation, Neoral, in liver transplant recipients with external biliary diversion. Transplant Proc 26:2977–2978

  13. Weizman Z, Durie PR, Kopelman HR, Vesely SM, Forstner GG (1986) Bile acid secretion in cystic fibrosis: evidence for a defect unrelated to fat malabsorption. Gut 27:1043–1048

  14. Williams SGJ, Westaby D, Tanner MS, Mowat AP (1992) Liver and biliary problems in cystic fibrosis. Br Med Bull 48:877–892

Download references

Author information

Correspondence to K. K. C. Tan.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Tan, K.K.C., Uttridge, J.A., Trull, A.K. et al. Relative bioavailability of cyclosporin from conventional and microemulsion formulations in heart-lung transplant candidates with cystic fibrosis. Eur J Clin Pharmacol 48, 285–289 (1995). https://doi.org/10.1007/BF00198313

Download citation

Key words

  • Cyclosporin
  • Cystic fibrosis
  • pharmacokinetics
  • bioavailability
  • formulation
  • transplantation